13/10/06
2006 3rd quarter: sales up 9%

€ millions  2006  2005  % change Q3 Sales 24.89 22.76 9% France, including overseas dependencies 11.96 10.83 10% Subsidiaries (1)   9.73   8.88 10% Distributors   3.20  3.05...

12/09/06
1st Half Year 2006 : A 14% increase in sales,major R&D efforts: ORALAIR® Grasses within sight

The Board of Directors, meeting on 12 September 2006, under the chairmanship of Albert SAPORTA, approved the consolidated financial statements at 30 June 2006, prepared in accordance with international standards.  The...

15/03/06
1st Half Year 2006 : A 14% increase in sales

The Board of Directors, meeting on 12 September 2006, under the chairmanship of Albert SAPORTA, approved the consolidated financial statements at 30 June 2006, prepared in accordance with international standards.  The...

12/04/06
1st quarter 2006 :Strong sales growth of 17%

€ millions 2006 Q1 2005 Q1 % growth France 20,66 17,70 +17% Subsidiaries (1) 11,47 9,66 +19% (2) Distributors 3,46 2,94 +18% Total 35,59 30,30 +17%

(1) Germany, Italy, Spain/Portugal, Belgium (2) + 9%...

15/03/06
2005: Further strong growth in profit Oralair study successful

The Board of Directors, meeting on 14 March 2006, under the chairmanship of Albert Saporta, approved the 2005 consolidated financial statements prepared in accordance with international accounting standards.

€millions 2004 ...

09/03/06
Positive results of study recombinant Bet v 1

Successful proof of concept study of recombinant Bet v 1 efficacy in desensitization against birch pollen allergy

Objective: Birch pollen is one of the most frequent cause of Respiratory Allergy in Central Europe, Northern...

13/01/06
2005 sales: +18% (+15% organic). 2005 4th quarter sales: +14% (+10% organic)

(€millions) 2005 2004 % change 4th quarter 33.10 29.05 +14 France & Overseas territories 16.18 13.98 +16 Subsidiaries (1) 13.26 10.55 +26 Distributors (2) 3.66 4.52 -19 Full year ...

28/11/05
Stallergènes: the positive results of the grass pollen tablet study allow the active continuation of its development program.

The VO 34 study of rhino-conjunctivitis allergies to grass pollen (« hay fever») enables to conclude that the allergen tablet ORALAIR® Grasses induces, right from the first season of treatment, a 37% reduction(*) of symptoms and...

13/10/05
17% increase in 2005 3rd quarter Group sales

(€ millions)20052004% growth3rd quarter22.7619.42+17France & overseas territories10.839.33+16Subsidiaries (1)8.887.42+20Distributors3.052.67+14 9 months  78.89 65.63 +20France & overseas...

07/08/07
2005 1st Half-Year Group Sales Up 21%

(€millions)2004(3) 2005% changeQ2 sales21.1025.8322%France *10.7613.0721%Subsidiaries **7.369.9135%Distributors ***2.982.85(4%)1st half-year sales46.2056.1221%France *24.7530.7824%Subsidiaries **15.8919.5623%Distributors...

14/09/05
Excellent half year performance,Operating profit up 39%,Net profit up 58%

The Board of Directors, meeting on 13 September 2005, under the chairmanship of Albert SAPORTA approved the consolidated financial statements at 30 June 2005, prepared in accordance with the new accounting standards.  the...

14/04/05
Significant increase in 2005 1st quarter sales: + 21%

€ millions 2005 Q 1 2004 Q1 % growth France 17.70 13.99 + 27% Subsidiaries (1) 9.66 8.54 + 13% Distributors 2.94 2.58 + 14% Total 30.30 25.11 + 21%

(1) Germany, Belgium, Italy, Spain and Portugal Stallergènes...

01/04/05
Project to buy back shares

Stallergènes announces its intention to implement shortly the share buyback programme adopted at its General Meeting of December 20, 2004.  This should take the form of an Offre Publique d’Achat Simplifiée (Simplified Public...

17/03/05
2004 Financial Year Results,Strong growth in profitability enabling an acceleration in R&D efforts,Strengthening of commercial positions in Spain and Portuga

The Board of Directors, meeting on 15 March 2005 under the chairmanship of Albert Saporta, approved the 2004 consolidated financial statements of Stallergenes Group.

(€ millions) 2003 % of sales 2004     ...

14/10/04
2004 3rd Quarter Sales Up 12%

(€ millions)2004 2003 % Change3rd quarter19.4817.39+12France & Overseas Territories9.348.42+11Subsidiaries (1)7.476.63+13Distributors2.672.34+14 9-months at 30 September  65.81 59.94 +10France &...

07/09/04
2004 Half year results:Further improvement in profitability

The Board of Directors, meeting on 2 September 2004 under the chairmanship of Albert Saporta approved the consolidated financial statements at 30 June 2004.

(€ millions)20041st half year %of sales20031st half year%of sales%...

15/04/04
2004 1st Quarter Sales Up 8 %

(€ millions) 2004 Q1 2003 Q1 % change  France * 13.99 11.84 18%  Subsidiaries ** 8.54 8.38 2%  Distributors ** 2.58 3.09 (17%) Total sales 25.11 23.31 8%

* France including French overseas...

07/08/07
2003 Financial Year Results: Continuing growth in profitability,Acceleration of R&D programme,Continued reduction in borrowings

The Board of Directors, meeting on 16 March 2004 under the chairmanship of Albert Saporta, approved Stallergènes financial statements for the financial year ending 31 December 2003.

(€ millions) 2002 % Sales 2003 % Sales...

15/07/04
2004 1st Half-Year Group Sales Up 9%

(€ millions)20032004 % increaseQ2 sales19.2421.2210%France *9.6210.7612%Subsidiaries **7.197.484%Distributors ***2.432.9823%1st HY sales 42.5546.339%France *21.4624.7515%Subsidiaries **15.5716.023%Distributors...

14/01/04
2003 4th quarter sales up 9% ~ 2003 full year sales up 14%

€ millions 2003 2002 Var. % 4th quarter sales 25,75 23,59 9 France & Overseas territoriesSubsidiaries (1)Distributors (2) 11,7710,263,72 10,829,533,24 9815 Full year sales 85,69 74,90 14 France & Overseas...

15/10/03
2003 3rd quarter sales up 11%

€ millions 2003 2002  % growth 3rd quarter sales 17.39 15.70 11 France & Overseas territories 8.42 7.31 15 Subsidiaries (1) 6.63 6.28 6 Distributors 2.34 2.11 11   Cumulative sales at end September...

24/09/03
2003 1st Half-Year Group Results:Continuation of improving results

The Board of Directors, meeting on 24 September 2003 under the chairmanship of Albert Saporta, approved Stallergènes Group’s consolidated financial statements for the 1st half-year ending 30 June 2003.

(€ millions) 2003...

25/08/03
Allergy to mites:Agreement between Stallergenes and MERISTEM Therapeutics for recombinant allergens production

MERISTEM Therapeutics (Clermont-Ferrand - France) and Stallergenes (Antony - France) announce the signature of an agreement on the industrial feasibility and the production of two mites major allergens in plant.

This agreement...

15/07/03
1st Half-Year Group Sales Up 20%

(€ millions) 2002 2003 % Growth 2nd quarter 17.20 19.24 12% France * 7.99 9.62 20% Subsidiaries ** 6.77 7.19 6% Distributors *** 2.44 2.43 - 1st Half-Year 35.60 42.55 20% France * 17.18 21.46 25% Subsidiaries **...

10/08/07
Note d'information relative à un programme de rachat d'actions propres qui sera soumis à l'approbation de l'assemblée générale mixte des actionnaires le 18 juin 2003.

Only available in French

Société anonyme au capital de 12.160.000 eurosSiège social : 6, rue Alexis de Tocqueville - 92183 Antony393 709 860 R.C.S. Nanterre

En application des articles L 621-8 du Code Monétaire et Financier,...

12/05/03
BIOMAY and Stallergenes have signed a patent licence agreement

Today, Biomay (Vienna – Austria) and Stallergenes (Antony – France) announce the signature of a patent licence agreement on the gene encoding for the birch pollen major allergen Bet v 1a.

This agreement represents an important...

14/04/03
Continued strong growth in sales, 2003 1st Quarter Group sales up 27%

(€ millions) 2003 Q1 % sales 2002 Q1 % sales % increase France *International - subsidiaries **International - distributors *** 11.848.383.09 50.836.013.2 9.197.221.99 50.039.210.8 29%16%55% Total Group sales 23.31 100.0 18.40...

14/04/03
2003 1st Quarter Group sales up 27%: Continued strong growth in sales

(€ millions) 2003 Q1 % sales 2002 Q1 % sales % increase France * International - subsidiaries ** International - distributors *** 11.84 8.38 3.09 50.8 36.0 13.2 9.19 7.22 1.99 50.0 39.2 10.8 29% 16% 55% Total...

15/03/03
2002 results

Sales: +18%Net income increases twofold: 6.3% of salesNet debt down sharply: -40%

The Board of Directors' meeting of 18 March 2002 chaired by Albert Saporta issued the financial statements for the year 2002.

€...

10/08/07
Chiffre d'affaires du 3ème trimestre : + 27%,Chiffre d'affaires cumulé 9 mois : + 19%

Only available in French

En M€20012002Var. %CA 3ème trimestre12,3815,70+ 27 %France5,307,08+ 34 %Allemagne2,522,83+ 12 %Italie2,002,21  + 11 %Espagne0,660,82+ 24 %Autres pays1,902,76+ 45 %CA cumulé à fin septembre...

10/08/07
Résultats semestriels 2002:Accélération de la croissance, Poursuite de l'amélioration des résultats

Only available in French

Le Conseil d'Administration, qui s'est tenu le 24 septembre 2002, sous la présidence d'Albert Saporta a arrêté les comptes consolidés au 30 juin 2002.

En M€1er semestre2002en %du CA1er semestre2001en...

10/08/07
Chiffre d'affaires du 2ème trimestre : + 17%

Only available in French

En M€20012002Var. %CA 2ème trimestre14,7017,21+ 17 %France6,367,78+ 22 %Allemagne2,643,05+ 16 %Italie2,182,39  + 9 %Espagne0,700,86+ 23 %Autres pays2,823,13+ 11 %CA 1er semestre *30,6135,61+ 16...

10/08/07
Eva Barszcz-Begaud devient Directeur Marketing de Stallergenes

Only available in French

Eva Barszcz-Begaud, 36 ans, rejoint Stallergènes, leader français du traitement de l'allergie par immunothérapie allergénique en tant que Directeur Marketing.

Diplômée d'une Maîtrise de Biologie...

10/08/07
Chiffre d'affaires du 1er trimestre 2002 : +16%,Maintien du rythme soutenu de croissance

Only available in French

En M€20012002Var. %France7,479,04+ 21%Allemagne2,943,25+ 11%Italie2,152,68+ 25%Espagne0,860,79- 8%Autres pays2,492,64+ 6%CA consolidé 1er trimestre15,9118,40+ 16%

Au 1er trimestre 2002, les ventes ont...

10/08/07
Résultats 2001: Accélération de la croissance,Nette amélioration de la rentabilité

Only available in French

Le Conseil d'Administration, qui s'est tenu le 19 mars 2002, sous la présidence d'Albert Saporta a arrêté les comptes consolidés au 31 décembre 2001.

En M€2001En %du CA2000En % du CA2001/2000variation...

10/08/07
Chiffre d'affaires 2001 :croissance record +15%

Only available in French

(M€)20012000Variation 2001/00         %CA 4ème trimestre 20,2717,84+14France8,667,35+18Allemagne3,743,45+8Italie2,762,42+14Espagne1,130,98+15Autres pays3,983,64+10CA...